To compare the efficacy and safety of NPB-01 in patients with autoimmune encephalitis refractory to steroid pulse therapy using steroid pulse therapy as a control.

开始日期2022-03-03

申办/合作机构

Nihon Pharmaceutical Co., Ltd.

JPRN-jRCT2080224838 / Completed临床2期

Phase II exploratory study of NPO-13 in patients undergoing colonoscopy

开始日期2019-08-26

申办/合作机构

Nihon Pharmaceutical Co., Ltd.

NCT04097574 / Completed临床2期

Phase II Study of NPO-13 in Patients Undergoing Colonoscopy

This study will investigate the safety, efficacy and dose-response of NPO-13 in subjects with moderate to severe colonic spasm during colonoscopy. An intraluminal spraying of NPO-13 dosed up to twice into ascending or sigmoid colon. The colonic spasm will be assessed by an independent committee using recorded video images. The study consists of a screening visit window, 1-day treatment phase and 1-week follow-up phase.

开始日期2019-08-26

申办/合作机构

Nihon Pharmaceutical Co., Ltd.

100 项与 Nihon Pharmaceutical Co., Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Nihon Pharmaceutical Co., Ltd. 相关的专利（医药）

登录后查看更多信息

项与 Nihon Pharmaceutical Co., Ltd. 相关的文献（医药）

2020-01-01·Journal of oleo science4区 · 农林科学

The Impact of Ascidian (<i>Halocynthia roretzi</i>)-derived Plasmalogen on Cognitive Function in Healthy Humans: A Randomized, Double-blind, Placebo-controlled Trial

4区 · 农林科学

Article

作者: Watanabe, Hirofumi ; Wada, Tatsuya ; Mano, Takashi ; Okawara, Masaki ; Suzuki, Naoko ; Matahira, Yoshiharu ; Takara, Tsuyoshi

OBJECTIVES:

Plasmalogen, phospholipids with previously shown associations with dementia, has attracted attention as a substance found in some studies to improve cognitive function. The effects of ascidian-derived plasmalogens on cognitive performance improvement were assessed in a randomized, double-blind, placebo-controlled study including Japanese adult volunteers with mild forgetfulness.

METHODS:

Participants consumed either the active food containing ascidian-derived plasmalogen (1 mg as plasmalogen) or the placebo food for 12 weeks, and their cognitive performance was assessed by Cognitrax. Participants were randomly allocated into the intervention (ascidian-derived plasmalogen; 8 males, and 17 females; 45.6 ± 11.1 years) or the placebo (9 males, and 15 females; mean age, 46.4 ± 10.8 years) group.

RESULTS:

Compared to the placebo group, the intervention group showed a significant increase score in composite memory (eight weeks: 3.0 ± 16.3 points, 12 weeks: 6.7 ± 17.5 points), which was defined as the sum of verbal and visual memory scores.

CONCLUSIONS:

These results indicate the consumption of ascidian-derived plasmalogen maintains and enhances memory function. This study was registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR, registry no. UMIN000026297). This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

2019-12-01·Regenerative therapy3区 · 工程技术

Mesenchymal stem cells cultured under hypoxic conditions had a greater therapeutic effect on mice with liver cirrhosis compared to those cultured under normal oxygen conditions

3区 · 工程技术

ArticleOA

作者: Hara, Yukio ; Nakajima, Kenji ; Ogawa, Masahiro ; Terai, Shuji ; Watanabe, Takayuki ; Yamashita, Junji ; Takamura, Masaaki ; Kikuta, Junichi ; Takeuchi, Suguru ; Tsuchiya, Atsunori ; Nojiri, Shunsuke ; Kojima, Yuichi ; Ishii, Masaru

BACKGROUND:

Mesenchymal stem cells (MSCs) can be easily expanded. They can be acquired from medical waste such as adipose and umbilical cord tissues, are influenced by culturing conditions, and exert anti-inflammatory, antioxidant, anti-fibrotic, and angiogenic effects. We analyzed the multi-directional effects of MSCs cultured under hypoxic conditions and their underlying mechanisms in the treatment of liver cirrhosis in a mouse model.

METHODS:

Human bone marrow-derived MSCs cultured under hypoxic (5% O₂; hypoMSCs) and normoxic (21% O₂; norMSCs) conditions were compared by cap analysis of gene expression (CAGE) with or without serum from liver cirrhosis patients. The therapeutic effects of MSCs, including serum liver enzyme induction, fibrosis regression, and hepatic oxidative stress, were evaluated by injecting 1 × 10⁶, 2 × 10⁵, or 4 × 10⁴ MSCs/mouse into the tail veins of mice with carbon tetrachloride (CCl₄)-induced liver cirrhosis. Intravital imaging was performed with a two-photon excitation microscope to confirm the various MSC migration paths to the liver.

RESULTS:

CAGE analysis revealed that the RNA expression levels of prostaglandin E synthase (Ptges) and miR210 were significantly higher in hypoMSCs than in norMSCs. In vivo analysis revealed that both hypoMSCs and norMSCs reduced serum alanine aminotransferase, oxidative stress, and fibrosis compared to that in control mice in a dose-dependent manner. However, hypoMSCs had stronger therapeutic effects than norMSCs. We confirmed this observation by an in vitro study in which hypoMSCs changed macrophage polarity to an anti-inflammatory phenotype via prostaglandin E2 (PGE2) stimulation. In addition, miR210 reduced the rate of hepatocyte apoptosis. Intravital imaging after MSC administration showed that both cell types were primarily trapped in the lungs. Relatively a few hypoMSCs and norMSCs migrated to the liver. There were no significant differences in their distributions.

CONCLUSION:

The therapeutic effect of hypoMSCs was mediated by PGE2 and miR210 production and was greater than that of norMSCs. Therefore, MSCs can be manipulated to improve their therapeutic efficacy in the treatment of liver cirrhosis and could potentially serve in effective cell therapy. MSCs produce several factors with multidirectional effects and function as "conducting cells" in liver cirrhosis.

2018-06-01·The Journal of investigative dermatology1区 · 医学

Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models

1区 · 医学

Article

作者: Sasaoka, Tetsumasa ; Shinkuma, Satoru ; Nishie, Wataru ; Ujiie, Hideyuki ; Natsuga, Ken ; Shimizu, Hiroshi ; Ishikawa, Makoto ; Higashino, Hiroshi ; Iwata, Hiroaki

Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by autoantibodies to COL17. Currently, systemic corticosteroids are used as first-line treatments for BP; alternatively, intravenous administration of high-dose IgG (IVIG) has been shown to be effective for patients with steroid-resistant BP in clinical practice. However, the effect of IVIG on BP has not fully been investigated. To examine the effects and mechanisms of action of IVIG against BP, we performed IVIG experiments using two experimental BP mouse models. One is a passive-transfer BP model that reproduces subepidermal separation in neonatal mice by the passive transfer of IgGs against COL17, such as polyclonal or monoclonal mouse IgG or IgG from BP patients. The other is an active BP model that continuously develops a disease phenotype in adult mice. IVIG decreased pathogenic IgG and the disease scores in both models. Injected IVIG distributed throughout the dermis and the intercellular space of the lower epidermis. Notably, IVIG inhibited the increase of IL-6 in both models, possibly by suppressing the production of IL-6 by keratinocytes. These results suggest that the inhibitory effects of IVIG on BP are associated with the reduction of pathogenic IgG and the modulation of cytokine production.

项与 Nihon Pharmaceutical Co., Ltd. 相关的新闻（医药）

2024-04-03

·BioSpace

C-Suite Shuffle: Lonza Hires New CEO

Pictured: Shell game with business executives/Nicole Bean for BioSpace Welcome to the latest update about people coming and going from executive positions at biopharma companies that BioSpace covers, or who have been personally named in lawsuits. Lonza headlines this installment by luring a new CEO from another Swiss CDMO just days after the company made a splash by committing $1.2 billion to buy a massive biologics manufacturing facility in California. Japan’s Aculys also brought in a new CEO to replace an interim chief, while several other biopharma firms named clinical and regulatory bosses. Lonza Lonza, which is in process of acquiring one of the world’s largest biologics manufacturing plants from Roche for $1.2 billion, has hired Wolfgang Wienand to assume the role of CEO beginning this summer, replacing interim chief Albert Baehny. Wienand is currently CEO of Swiss CDMO Siegfried Holding. Baehny, Lonza’s board chair, has been in charge of Lonza since Pierre-Alain Ruffieux departed in September. He will retire following a transition period to Wienand’s leadership, according to the company. Trevi Therapeutics Trevi Therapeutics has named Margaret Garin VP of clinical development. Garin will lead the company’s development of its chronic cough treatments, including lead asset Haduvio, an investigational compound now in Phase IIa and Phase IIb trials for idiopathic pulmonary fibrosis and refractory chronic cough. Garin, a physician, had been executive director of clinical development at Bellus Health, which GSK acquired for $2 billion last year. Zephyr AI Startup precision medicine technology firm Zephyr AI has hired Rachael Brake as chief scientific officer. Brake is a former CSO of Corbus Pharmaceuticals, where she helped build an R&D team in precision medicine and immuno-oncology. Zephyr AI last month closed a $111 million Series A funding round from investors including Eli Lilly. KBI Biopharma JSR Life Sciences’ KBI Biopharma has hired Peter Carbone as chief quality officer to lead the company’s quality, compliance and regulatory affairs efforts. The CDMO recently inked a strategic alliance with Argonaut Manufacturing Services to augment KBI’s sterile fill-finish services. Last year, the firm launched a new suite of monoclonal antibody development and manufacturing services. Aculys Pharma Aculys Pharma has brought in Hidemasa Tanigaki as CEO and representative director. Tanigaki, who replaces interim chief Takeshi Takahashi, joins Aculys after serving as head of Takeda’s gastrointestinal business for two years. He is a former CEO and president of Nihon Pharmaceutical. Tokyo-based Aculys in October reported positive interim results of a Phase III trial of a diazepam nasal spray for treating epileptic seizures in a pediatric population. Neil Versel is the business editor at BioSpace. You can reach him at neil.versel@biospace.com. Follow him on LinkedIn or X.

高管变更临床结果临床2期临床3期并购

2021-08-05

·GlobeNewswire

A Robust Neuromyelitis Optica Spectrum Disorder Pipeline Domain Witnesses Several Novel and Promising Therapies in Different Stages of Clinical Development Expected to Enter the Market by the Next Dec

Los Angeles, USA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- A Robust Neuromyelitis Optica Spectrum Disorder Pipeline Domain Witnesses Several Novel and Promising Therapies in Different Stages of Clinical Development Expected to Enter the Market by the Next Decade DelveInsight’s analysis demonstrates a robust Neuromyelitis Optica Spectrum Disorder Pipeline with 15+ active players in the domain working on 15+ pipeline therapies. DelveInsight’s ‘Neuromyelitis Optica Spectrum Disorder Pipeline Insights’ report presents an exhaustive coverage of the available therapies, Neuromyelitis Optica Spectrum Disorder emerging therapies in different phases of clinical development, key companies working in the Neuromyelitis Optica Spectrum Disorder pipeline domain, and future potential of the space. Some of the notable pointers extracted from the Neuromyelitis Optica Spectrum Disorder Pipeline report: Request for Sample to know more about the therapies expected to make grab the maximum patient pool @ Neuromyelitis Optica Spectrum Disorder Emerging Therapies and Forecast The Neuromyelitis Optica Spectrum Disorder Pipeline reports lays down a comprehensive structure of the ongoing clinical trials, partnerships taking place in the domain, recent happenings in space, and growth prospects across the Neuromyelitis Optica Spectrum Disorder domain. Neuromyelitis Optica Spectrum Disorder Overview Neuromyelitis Optica Spectrum Disorder (NMOSD), also referred to as Devic disease, is a chronic condition that causes inflammation of the optic nerve and spinal cord thereby affecting the brain and spinal cord. The condition is an autoimmune disorder, however, the exact pathophysiology and cause of the autoimmunity remain unclear. Discover more about the disease, treatments, and pipeline therapies @ NMOSD Pipeline Assessment Neuromyelitis Optica Spectrum Disorder Pipeline Drugs Request for Sample to know more @ Neuromyelitis Optica Spectrum Disorder Pipeline Analysis, Key Companies, and Futuristic Trends Neuromyelitis Optica Spectrum Disorder Therapeutics Assessment The Neuromyelitis Optica Spectrum Disorder Pipeline report presents a holistic picture of the Neuromyelitis Optica Spectrum Disorder emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action. By Product Type By Stage By Molecule Type By Route of Administration By Mechanism of Action By Targets For rich insights into merging therapies and assessment, visit NMOSD Pipeline Emerging Novel Therapies Scope of the Neuromyelitis Optica Spectrum Disorder Pipeline Report Coverage: GlobalKey Players: Alexion Pharmaceuticals, RemeGen, Reistone Biopharma, Chord Therapeutics, Nihon Pharmaceuticals, Harbour BioMed, Bio-Thera Solutions, Abide Therapeutics, Bionure, Boston Pharmaceuticals, and TG Therapeutics among others.Key Neuromyelitis Optica Spectrum Disorder Pipeline Therapies: Ravulizumab, Telitacicept, SHR1459, CRD1, HBM9161, BAT4406F, ABX-1431, BN201, ARN-6039, and Ublituximab among others.Discover more about the scope of the report @ Neuromyelitis Optica Spectrum Disorder Emerging Therapies, Treatments, and Ongoing Clinical Trials Table of Contents Learn more about the report offerings @ Neuromyelitis Optica Spectrum Disorder Pipeline Therapies and Emerging Trends Audit the market before venturing with DelveInsight’s Due Diligence Services Related Reports Neuromyelitis Optica Spectrum Disorder MarketDelveInsight's "Neuromyelitis Optica Spectrum Disorder (Neuromyelitis Optica Spectrum Disorder) Market Insights, Epidemiology and Market Forecast-2028" report. Pompe Disease Market Insight Epidemiology And Market ForecastDelveInsight's "Pompe Disease Market Insights, Epidemiology and Market Forecast-2028" report. Spinal Muscular Atrophy Sma Market Insight Epidemiology And Market ForecastDelveInsight's 'Spinal Muscular Atrophy (SMA) - Market Insights, Epidemiology and Market Forecast-2028' report. Spinocerebellar Ataxias Market Insights Epidemiology And Market ForecastDelveInsight's 'Spinocerebellar Ataxia (SCA) - Market Insights, Epidemiology and Market Forecast-2028’ report. Acute Ischemic Stroke Market InsightsDelveInsight’s ‘Acute Ischemic Stroke (AIS) - Market Insights, Competitive Landscape and Market Forecast–2026’ report. Adult Intraventricular Hemorrhage MarketDelveInsight’s ‘Adult Intraventricular Haemorrhage Market Insights, Competitive Landscape and Market Forecast-2026’ report. Carotid Stenotic Scan Devices MarketDelveInsight’s ‘Carotid Stenotic Scan Devices Market Insights, Competitive Landscape and Market Forecast-2026’ report. Browse through our posts Dynamics Of Schizophrenia MarketAlzheimer’s Disease Market LandscapeAdvancements in Neuromodulation in the Neurological Disorders MarketDeep Brain Stimulation Devices and Changing Market Landscape About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News

100 项与 Nihon Pharmaceutical Co., Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Nihon Pharmaceutical Co., Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Human Normal Immunoglobulin (Nihon Pharmaceutical Co., Ltd.)	低白蛋白血症更多	批准上市
冻干人抗凝血酶Ⅲ浓缩物(Takeda)	抗凝血酶III缺乏症更多	批准上市
TK-21 ( nAChRs )	重症肌无力更多	临床前
薄荷脑 ( TRPA1 x TRPM8 )	胃腺瘤更多	无进展
左旋薄荷醇 ( TRPA1 x TRPM8 x κ opioid receptor )	肠道疾病更多	无进展